<p><sup>a</sup>Fisher’s exact test refers to comparison between all ALS patients and healthy controls</p><p><sup>b</sup>Fisher’s exact test refers to comparison between all groups (ALS patients with spinal and bulbar onset and healthy controls)</p><p><sup>c</sup>Mann-Whitney-<i>U</i>-test refers to comparison between all ALS patients and healthy controls or between ALS patients with spinal and bulbar onset.</p><p><sup>d</sup>Kruskal-Wallis analysis of variances on ranks between healthy controls, ALS patients with bulbar and spinal onset.</p><p><sup>†</sup>Post-hoc comparison for <i>p</i><0.05 using Mann-Whitney-<i>U</i>-test: <i>p</i><0.001 for ALS patients with spinal onset compared with healthy controls.</p><p><sup>e</sup>ALSFRS-R, revise...
<p>COWAT = Controlled Oral Word Association Test; VFI = verbal fluency index; MoCA = Montreal Cognit...
<p>N = Number of subjects, Ln = natural log transform. EES score: 1 = defined as possible ALS, 2 = p...
International audienceObjectives: (1) Adapt the ECAS into Greek, validate it in ALS patients and com...
<p>F-values indicate significant differences across groups; Tukey post hoc tests compare differences...
<p>Values are mean ± standard deviation [range] or number (%). P<sup>1</sup> = differences between ...
<p>Numbers are mean ± standard deviation (range) or number. °Disease progression rate = (48-ALSFRS-r...
<p>*across subgroups of ALS.</p><p>ALSFRS-R = revised Amyotrophic Lateral Sclerosis Functional Rat...
<p><sup>a</sup>Mann-Whitney-<i>U</i>-test between healthy controls and all ALS patients</p><p><sup>b...
<p>Data are presented as mean ± standard deviation. Differences between groups are represented as <s...
<p>Clinical details of subjects. ALS, amyotrophic lateral sclerosis; F, female; g, grams; l, litre; ...
<p>ALS, amyotrophic lateral sclerosis; ALSFRS-R, revised ALS functional rating scale; ALSSS, ALS sev...
<p>ALS, amyotrophic lateral sclerosis; ALSFRS-R, revised ALS functional rating scale; ALSSS, ALS sev...
<p>M: male; F: Female. B: bulbar onset; L: limb onset; MFO: interval from the observation of initial...
a<p>Progression rate = (40-ALSFRS)/disease duration (months).</p>b<p>ALSFRS-ALS functional rating sc...
International audienceObjectives: Amyotrophic lateral sclerosis (ALS) is a rare disease with heterog...
<p>COWAT = Controlled Oral Word Association Test; VFI = verbal fluency index; MoCA = Montreal Cognit...
<p>N = Number of subjects, Ln = natural log transform. EES score: 1 = defined as possible ALS, 2 = p...
International audienceObjectives: (1) Adapt the ECAS into Greek, validate it in ALS patients and com...
<p>F-values indicate significant differences across groups; Tukey post hoc tests compare differences...
<p>Values are mean ± standard deviation [range] or number (%). P<sup>1</sup> = differences between ...
<p>Numbers are mean ± standard deviation (range) or number. °Disease progression rate = (48-ALSFRS-r...
<p>*across subgroups of ALS.</p><p>ALSFRS-R = revised Amyotrophic Lateral Sclerosis Functional Rat...
<p><sup>a</sup>Mann-Whitney-<i>U</i>-test between healthy controls and all ALS patients</p><p><sup>b...
<p>Data are presented as mean ± standard deviation. Differences between groups are represented as <s...
<p>Clinical details of subjects. ALS, amyotrophic lateral sclerosis; F, female; g, grams; l, litre; ...
<p>ALS, amyotrophic lateral sclerosis; ALSFRS-R, revised ALS functional rating scale; ALSSS, ALS sev...
<p>ALS, amyotrophic lateral sclerosis; ALSFRS-R, revised ALS functional rating scale; ALSSS, ALS sev...
<p>M: male; F: Female. B: bulbar onset; L: limb onset; MFO: interval from the observation of initial...
a<p>Progression rate = (40-ALSFRS)/disease duration (months).</p>b<p>ALSFRS-ALS functional rating sc...
International audienceObjectives: Amyotrophic lateral sclerosis (ALS) is a rare disease with heterog...
<p>COWAT = Controlled Oral Word Association Test; VFI = verbal fluency index; MoCA = Montreal Cognit...
<p>N = Number of subjects, Ln = natural log transform. EES score: 1 = defined as possible ALS, 2 = p...
International audienceObjectives: (1) Adapt the ECAS into Greek, validate it in ALS patients and com...